Vardenafil: A Potential Drug To Protect Gastric Mucosa

Main Category: GastroIntestinal / Gastroenterology
Article Date: 19 Nov 2009 - 6:00 PDT

email to a friend   printer friendly   opinions  

Indomethacin has been proved by epidemiological and experimental studies to be closely associated with peptic ulcer development. Vardenafil is a potent phosphodiesterase 5 inhibitor and its effects on the gastric mucosa have not been reported.

A research article published in the World Journal of Gastroenterology addresses this problem. The research team, led by Dr. Karakaya MD from Zonguldak Karaelmas University, designed an experimental study in rats in which they used vardenafil to study gastric mucosal protection against the harmful effects of indomethacin.

Multiple agents have been used to prevent NSAID-induced peptic ulcer. This work is the first experimental study that shows the beneficial effects of Vardenafil (a phosphodiesterase type V inhibitor) on NSAID-induced gastric ulcer. The gastroprotective effect of vardenafil against NSAID-induced peptic ulcer is dose-dependent. The study results suggest that vardenafil might be used as a potential therapeutic drug to prevent NSAID-induced gastric ulcer formation.

Reference: Karakaya K, Hanci V, Bektas S, Can M, Ucan HB, Emre AU, Tascılar O, Ozkocak Turan I, Comert M, Irkorucu O, Karadeniz Cakmak G. Mitigation of indomethacin-induced gastric mucosal lesions by a potent specific type V phosphodiesterase inhibitor. World J Gastroenterol 2009; 15(40): 5091-5096 http://www.wjgnet.com/1007-9327/15/5091.asp

Source: Lin Tian
World Journal of Gastroenterology

• Additional
• References
• Citations